National Cheng Kung University-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5